Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134197 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of Lupartumab Amadotin (BAY1129980)
A Phase 1 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT02134197 is a Phase 1 study that was terminated before completion, run by Bayer. The registered enrollment target is 69 participants.
The verdict
NCT02134197, a Phase 1 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate: * The side effects of BAY1129980 when given every 21 days different dose levels. * Determine the dose level of BAY1129980 that should be tested in future clinical research studies. * Measure how much BAY1129980 is in the blood at specific times after administration. * If treatment with BAY1129980 shows any effect on reducing the tumor growth. * If there are specific biomarkers that might be able to explain why some patients respond to treatment and others do not. * If treatment with BAY1129980 causes an immune response from the body against the drug (immunogenicity).
Interventions
- DRUG Lupartumab Amadotin (BAY1129980)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-05-22 |
| Est. Completion | 2018-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134197
The ClinicalTrials.gov registry entry for NCT02134197 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lupartumab Amadotin (BAY1129980) is the first listed.
NCT02134197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134197 about?
NCT02134197 is a clinical study titled "Dose-escalation Study of Lupartumab Amadotin (BAY1129980)". The purpose of this study is to evaluate: * The side effects of BAY1129980 when given every 21 days different dose levels. * Determine the dose level of BAY1129980 that should be tested in future clinical research studies. * Measure how much BAY1129980 is in the blood at specific times after admini...
What is the current status of trial NCT02134197?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2014-05-22. Estimated completion is 2018-08-30.
What interventions are being tested in trial NCT02134197?
The interventions under investigation include: Lupartumab Amadotin (BAY1129980) (DRUG).
Who is sponsoring clinical trial NCT02134197?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.